A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia

Stephen Couban

doi:10.1016/j.clml.2021.06.011

A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia

Stephen Couban

Pharmacology, Toxicology and Pharmaceutics

科研成果: 期刊稿件 › 文章 › 同行评审

4 引用（Scopus）

源语言	英语
页（从-至）	766-774
页数	9
期刊	Clinical Lymphoma, Myeloma and Leukemia
卷	21
期	11
DOI	https://doi.org/10.1016/j.clml.2021.06.011
出版状态	已出版 - 11月 2021

!!!ASJC Scopus Subject Areas

血液学
肿瘤学
癌症研究

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.1016/j.clml.2021.06.011

其它文件与链接

指纹

探究 'A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia' 的科研主题。它们共同构成独一无二的指纹。

引用此

A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia. / Couban, Stephen.
在: Clinical Lymphoma, Myeloma and Leukemia, 卷 21, 号码 11, 11.2021, 页码 766-774.

科研成果: 期刊稿件 › 文章 › 同行评审

Couban, S 2021, 'A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia', Clinical Lymphoma, Myeloma and Leukemia, 卷 21, 号码 11, 页码 766-774. https://doi.org/10.1016/j.clml.2021.06.011

@article{4850f6068a0a420a82eb1e20e35427dd,

title = "A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia",

keywords = "Chronic lymphocytic leukemia, Ibrutinib, Bendamustine-rituximab, Phase III trial, Economic analysis",

author = "Stephen Couban",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",

year = "2021",

month = nov,

doi = "10.1016/j.clml.2021.06.011",

language = "English",

volume = "21",

pages = "766--774",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "11",

}

TY - JOUR

T1 - A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia

AU - Couban, Stephen

PY - 2021/11

Y1 - 2021/11

KW - Chronic lymphocytic leukemia, Ibrutinib, Bendamustine-rituximab, Phase III trial

KW - Economic analysis

UR - http://www.scopus.com/inward/record.url?scp=85111612266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85111612266&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2021.06.011

DO - 10.1016/j.clml.2021.06.011

M3 - Article

C2 - 34334330

AN - SCOPUS:85111612266

SN - 2152-2650

VL - 21

SP - 766

EP - 774

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 11

ER -